Introduction {#S1}
============

The hedgehog signaling pathway (HHSP) is an important pathway for growth and development, including promotion of primitive hematopoietic,^[@R1]^ neural,^[@R2]^ and mammary^[@R3]^ stem cells. It is also required to bring the hair follicle from the resting to the growth phase.^[@R4]^ Loss of heterozygosity and inactivation mutations in PTCH1 and SMO have been implicated in the development of the majority of basal cell carcinomas (BCCs)^[@R5]--[@R7]^ and in patients with basal cell nevus syndrome (BCNS).^[@R7],[@R8]^ Vismodegib (GDC-0449) is a synthetic small molecule inhibitor of SMO that blocks downstream HHSP target genes; it has favorable pharmaceutical properties and greater potency than cyclopamine.^[@R9],[@R10]^ A phase I dose-finding, safety, and tolerability study of vismodegib in patients with advanced BCC and solid tumors was conducted, demonstrating primarily mild to moderate side effects.^[@R6],[@R7]^ Here we report on our experience of treating two patients with advanced BCC participating in the phase I study^[@R6],[@R7]^ who have received ongoing daily treatment for 2.75--\>3 years without experiencing any significant side effects that might be anticipated with chronic HHSP inhibition.

Case Report \#1 {#S2}
===============

A 49-year-old Caucasian man presented to our clinic with BCC metastatic to the lung and lymph nodes of the left neck. Eight years earlier he had been treated with cryotherapy and imiquimod cream for BCCs on the neck. Approximately 6.5 years later, he underwent his first surgical excision of cutaneous BCC of the neck and margins were reportedly positive. Subsequently, he was found to have multifocal metastatic BCC in the lungs, confirmed by video-assisted thoracic surgery (VATS) removal of a 1.5 cm left lower lung mass 1 month before evaluation at our clinic. His medical history was otherwise unremarkable except for approximately 2 years of heavy drinking; he had since abstained for over 2 years.

Physical examination was significant for healed left flank scar from VATS, several hard, fixed palpable lymph nodes in the left posterior cervical chain measuring 1--3 cm, and a 3.1 cm hard fixed left supraclavicular lymph node. There were small cutaneous BCCs in the left supraclavicular region, left neck ([Figure 1](#F1){ref-type="fig"}A), and left forearm (one each). Computed tomography (CT) imaging revealed multiple pulmonary nodules (∼20, the largest was 1.4 cm) ([Figure 1](#F1){ref-type="fig"}B) and multiple left neck ([Figure 1](#F1){ref-type="fig"}C) and supraclavicular lymph node involvement (size ranging from 1.4 to 3.1 cm). Fluorine-18-2-fluoro-2-deoxy-D-glucose positron-emission tomography (PET)/CT imaging identified 3--5 hypermetabolic foci in the right and left lung (peak standardized uptake value \[SUV\] 12.3) and 10--15 hypermetabolic foci in the left neck and supraclavicular fossa (peak SUV 14.8).

Figure 1Baseline photograph and computed tomography (CT) images of Patient 1: A) photograph of left neck area at baseline; B) CT scan at baseline showing multifocal pulmonary nodules several of which were \>1 cm; C) CT scan at baseline showing left neck adenopathy \>1 cm.

The patient started receiving oral vismodegib 270 mg daily in October 2008. By January 2009, the patient had a confirmed partial response on CT by Response Evaluation Criteria in Solid Tumors (RECIST^[@R11]^) and a complete response on PET/CT (absence of hypermetabolic foci). By April 2009, only a 0.8 cm pulmonary nodule could be measured on CT scan. In December 2009, his vismodegib dose was increased to 300 mg daily when he transitioned from the phase I protocol to the extension study; with the transition to the extension study, the 270 mg dose was no longer available. He maintained a continuing partial response until January 2011 ([Figures 2](#F2){ref-type="fig"}A and [2](#F2){ref-type="fig"}B), when a left axilla metastasis (non-target progression by RECIST^[@R11]^) was identified and excised. As of October 2011, he continues on vismodegib 300 mg daily without evidence of progression or disease recurrence elsewhere with continued resolution of cutaneous BCC ([Figure 2](#F2){ref-type="fig"}C). His only drug-associated adverse events (AEs) according to the National Cancer Institute Common Toxicity Criteria (version 3.0) have been grade 2 dysgeusia, intermittent grade 1 muscle cramps and fatigue (diminished in frequency by calcium and magnesium supplementation), and grade 2 alopecia. During the phase I study this patient also reported drug-related grade 1 intermittent heartburn and grade 1 weight loss.

Figure 2Response photograph and computed tomography (CT) images of Patient 1: A) CT scan after approximately 28 months of treatment with vismodegib showing near complete resolution of all pulmonary nodules; B) CT scan after approximately 28 months of treatment with vismodegib showing resolution of left neck adenopathy.; C) recent photograph of left neck area following 31 months of treatment with vismodegib.

Case Report \#2 {#S3}
===============

A 49-year-old Caucasian man with BCNS and active multifocal cutaneous BCCs was referred to our clinic. He underwent multiple therapies for BCC beginning in his 30s including Mohs surgeries, some requiring skin grafting, and cryosurgeries. He had recently averaged 5--10 surgeries for BCC annually. Pertinent medical history included several family members with BCNS.

Physical examination was significant for healed surgical scars, and several BCCs of approximately 0.5 cm on the left cheek and the right and periorbital region. On high-resolution ultrasound (HRU), six sonographic abnormalities were identified, the largest measuring 0.5 cm in the longest dimension.

The patient started receiving oral vismodegib 270 mg daily in March 2008. By December 2008, the patient had complete resolution of all six skin lesions on his face. In November 2009, his vismodegib dose was increased to 300 mg daily when he transitioned from the phase I protocol to the extension study. After more than 3 years of continuous daily dosing with vismodegib, his only drug-associated AEs are grade 1 dysgeusia, intermittent grade 1 muscle cramps (diminished with exercise), and grade 1 alopecia. Grade 1 fatigue was also reported during the phase I study. The patient continues to receive vismodegib 300 mg daily.

Discussion {#S4}
==========

Inhibition of the HHSP has been shown to affect stem cells responsible for blood, mammary, and neural development. After at least 3 years of continuous daily dosing, these two patients have not experienced significant alteration in hematologic parameters, nor physical abnormalities of their pectoral regions. The drug-related AEs observed in these two patients are all grade 1 or 2, with dysgeusia, possibly due to an effect on taste bud papillae.^[@R12]^ Since our initial report on results treating advanced BCC \>18 months ago,^[@R6]^ these two patients have had no new BCCs develop for at least 2.25 and 3+ years, respectively, and are tolerating therapy well. Based on the pharmacokinetic and pharmacodynamic profile of vismodegib, a dose of 150 mg daily is under evaluation in further studies.^[@R7]^ Overall, based on data from these two patients, it appears that long-term vismodegib use in adults with advanced BCC can be an effective therapy with manageable AEs.
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